Posaconazole Echinocandin B0 CAS NO.171228-49-2

Min.Order Quantity:: 100 Kilogram

Purity:: 99%

Port:: China Main Port

Payment Terms:: L/C,D/A,D/P,T/T,MoneyGram,Other

Add to Inquiry Cart

Product Details

Keywords

RARECHEM AH PB 0251
171228-49-2
C37H42F2N8O4

Quick Details

ProName: Posaconazole Echinocandin B0
CasNo: 171228-49-2
Molecular Formula: C37H42F2N8O4
Appearance: powder
Application: 171228-49-2
DeliveryTime: Within 3-7 days
PackAge: Depended
Port: China Main Port
ProductionCapacity: 300 Kilogram/Month
Purity: 99%
Storage: Refrigerator
Transportation: by air or by sea
LimitNum: 100 Kilogram
Valid Period: 6 month
Application: Multipurpose intermediate
Application: ISO/9001 Certificate

Superiority

posaconazole basic information

pharmacological effects pharmacokinetics clinical indications and usage

product name:	posaconazole
synonyms:	posaconazole;2,5-anhydro-1,3,4-trideoxy-2-c-(2,4-difluorophenyl)-4-[[4-[4-[4-[1-[(1s,2s)-1-ethyl-2-hydroxypropyl]-1,5-dihydro-5-oxo-4h-1,2,4-triazol-4-yl]phenyl]-1-piperazinyl]phenoxy]methyl]-1-(1h-1,2,4-triazol-1-yl)-d-threo-pentitol;noxafil;sch 56592;4-[4-[4-[4-[[(3r,5r)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2s,3s)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one;hydroxypropyl]-2,4-dihydro-3h-1,2,4-triazol-3-one;posaconazole for research;1-((1s,2s)-1-ethyl-2-hydroxypropyl)-4-{4-[4-(4-{[(5s,3r)-5-(2,4-difluorophenyl)-5-(1,2,4-triazolylmethyl)oxolan-3-yl]methoxy}phenyl)piperazinyl]phenyl}-1,2,4-triazolin-5-one
cas:	171228-49-2
mf:	c37h42f2n8o4
mw:	700.78
einecs:	200-659-6
product categories:	chiral reagents;intermediates & fine chemicals;pharmaceuticals;api;noxafil;inhibitors
mol file:	171228-49-2.mol

posaconazole chemical properties

mp	170-1720c
storage temp.	-20°c freezer
cas database reference	171228-49-2(cas database reference)

safety information

hazard codes	f,t
risk statements	11-23/24/25-39/23/24/25
safety statements	7-16-36/37-45
hazardous substances data	171228-49-2(hazardous substances data)

msds information

posaconazole usage and synthesis

pharmacological effects	posaconazole (posaconazole) is derived from itraconazole. it is currently subject to iii phase clinical trials. its pharmacological effects are similar with azoles, but compared with itraconazole, it has a stronger inhibitory effect on the c14 demethylation of steroid, especially for aspergillus.
pharmacokinetics	studies on dosage and dosage protocol have shown that the rate of absorption and elimination rate is in line with the single-compartment model. there are significant differences on the relative bioavailability of different doses of oral suspension. it can be taken separately (every 12 hours or every 6 hours) which can significantly improve the bioavailability with the protein binding rate of 98% to 99%. with respect to tablets, the bioavailability of suspensions increase and food can significantly improve the speed and extent of absorption of drug absorption. an investigation of renal dysfunction on the pharmacokinetics of the drug study results has showed that the drug can’t be removed by hemodialysis without being affected by hemodialysis. single-dose study has showed that patients with varying degrees of chronic kidney disease have no necessity for dosage adjustment. the half-life of this is about 25 hours which can be primarily metabolized by the liver.
clinical indications and usage	it can be clinically used for the treatment of aspergillosis, zygnmycosis, and fusariumsis and can also be used for infection caused by part of fluconazole-resistant candida genus. studies have shown that posaconazole can widely and effectively applied to the treatment of phaeohyphomycosis and improve the infection survival rate of dermatitidis infection in a dose-dependent manner. the drug, as second-line drugs, has an effective rate of 44% to 78% against the invasive aspergillosis which is resistant to amphotericin b and itraconazole. it also has an effective rate of 71% against the zygomycete fungi. the drug is an oral suspension with the recommended dose of 200mg and 4 times per day with meals and taken orally for 7 to 10 days. this dose can also be maintained or changed to 400mg with oral administration of 2 times per day. the steady-state plasma concentration can reach within 7 to 10 days. the above information is edited by the chemicalbook of dai xiongfeng.
chemical properties	white solid
usage	orally active triazole antifungal.
usage	posaconazole is a sterol c14ɑ demethylase inhibitor with an ic50 of 0.25 nm

service we provide:

1. mixed container, we can mix different items in one container.

2. quality control, before shipment, free sample for test. after shipment, keep sample for 3 years

3. prompt shipment with professional documents

4. packing as your request, with photo before shipment

Details

exhibition in shanghai

we have clients throughout the world：

professional service and rich experience make customers feel at ease, adequate stock and fast delivery meet your desire.

our laboratoy

we have our own independent lab test center：

this makes sure that our technology support is reliable and authoritative.all of self-owned fine chemicals are manufactured strictly in accordance with international standard.,and also has scientific cooperation with local colleges and institutes.